Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Autoantibody mediated deficiency of IL-36-receptor antagonist in a subset of patients with psoriasis and psoriatic arthritis.
Hoffmann MC, Fadle N, Regitz E, Kos IA, Cetin O, Lesan V, Preuss KD, Zaks M, Stöger E, Zimmer V, Klemm P, Assmann G, Pfeifer J, Bittenbring JT, Bewarder M, Vogt T, Pföhler C, Thurner B, Kessel C, Thurner L. Hoffmann MC, et al. Among authors: thurner l. Immunol Lett. 2024 Dec;270:106926. doi: 10.1016/j.imlet.2024.106926. Epub 2024 Sep 10. Immunol Lett. 2024. PMID: 39265919 Free article.
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, Borchmann P, Viardot A, Soekler M, Keller U, Schmidt C, Truemper L, Mahlberg R, Marks R, Hoeffkes HG, Metzner B, Dierlamm J, Frickhofen N, Haenel M, Neubauer A, Kneba M, Merli F, Tucci A, de Nully Brown P, Federico M, Lengfelder E, di Rocco A, Trappe R, Rosenwald A, Berdel C, Maisenhoelder M, Shpilberg O, Amam J, Christofyllakis K, Hartmann F, Murawski N, Stilgenbauer S, Nickelsen M, Wulf G, Glass B, Schmitz N, Altmann B, Loeffler M, Pfreundschuh M; FLYER Trial Investigators; German Lymphoma Alliance. Poeschel V, et al. Among authors: thurner l. Lancet. 2019 Dec 21;394(10216):2271-2281. doi: 10.1016/S0140-6736(19)33008-9. Lancet. 2019. PMID: 31868632 Clinical Trial.
Progranulin antibodies in autoimmune diseases.
Thurner L, Preuss KD, Fadle N, Regitz E, Klemm P, Zaks M, Kemele M, Hasenfus A, Csernok E, Gross WL, Pasquali JL, Martin T, Bohle RM, Pfreundschuh M. Thurner L, et al. J Autoimmun. 2013 May;42:29-38. doi: 10.1016/j.jaut.2012.10.003. Epub 2012 Nov 11. J Autoimmun. 2013. PMID: 23149338
Proinflammatory progranulin antibodies in inflammatory bowel diseases.
Thurner L, Stöger E, Fadle N, Klemm P, Regitz E, Kemele M, Bette B, Held G, Dauer M, Lammert F, Preuss KD, Zimmer V, Pfreundschuh M. Thurner L, et al. Dig Dis Sci. 2014 Aug;59(8):1733-42. doi: 10.1007/s10620-014-3089-3. Epub 2014 Mar 4. Dig Dis Sci. 2014. PMID: 24591016
LRPAP1 is a frequent proliferation-inducing antigen of BCRs of mantle cell lymphomas and can be used for specific therapeutic targeting.
Thurner L, Hartmann S, Fadle N, Kemele M, Bock T, Bewarder M, Regitz E, Neumann F, Nimmesgern A, von Müller L, Pott C, Kim YJ, Bohle RM, Wasik M, Schuster SJ, Hansmann ML, Preuss KD, Pfreundschuh M. Thurner L, et al. Leukemia. 2019 Jan;33(1):148-158. doi: 10.1038/s41375-018-0182-1. Epub 2018 Jun 28. Leukemia. 2019. PMID: 29955130
89 results